Company News: Pfizer

Share this article:

A study conducted by researchers at the University of Washington and published in medical journal The Lancet has found that a popular injectable contraceptive in Africa doubles the risk of women becoming infected with H.I.V. Nearly 4,000 couples who use the injectable were studied, hailing from countries scattered around Africa—Zambia, South Africa and Uganda, to name a few—and it was found that for women who are already H.I.V.-positive, their male partners were twice as likely to become infected than if their partner used no contraception at all. The branded version of the drug is Depo-Provera, manufactured by Pfizer, and reps for the pharma have yet to comment on the study.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions